Skip to main content
Top
Published in: Tumor Biology 12/2015

01-12-2015 | Research Article

Frequent methylation of the KLOTHO gene and overexpression of the FGFR4 receptor in invasive ductal carcinoma of the breast

Authors: Ashraf Dallol, Abdelbaset Buhmeida, Adnan Merdad, Jaudah Al-Maghrabi, Mamdooh A. Gari, Muhammad M. Abu-Elmagd, Aisha Elaimi, Mourad Assidi, Adeel G. Chaudhary, Adel M. Abuzenadah, Taoufik Nedjadi, Eramah Ermiah, Shadi S. Alkhayyat, Mohammed H. Al-Qahtani

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

Invasive ductal carcinoma of the breast is the most common cancer affecting women worldwide. The marked heterogeneity of breast cancer is matched only with the heterogeneity in its associated or causative factors. Breast cancer in Saudi Arabia is apparently an early onset with many of the affected females diagnosed before they reach the age of 50 years. One possible rationale underlying this observation is that consanguinity, which is widely spread in the Saudi community, is causing the accumulation of yet undetermined cancer susceptibility mutations. Another factor could be the accumulation of epigenetic aberrations caused by the shift toward a Western-like lifestyle in the past two decades. In order to shed some light into the molecular mechanisms underlying breast cancer in the Saudi community, we identified KLOTHO (KL) as a tumor-specific methylated gene using genome-wide methylation analysis of primary breast tumors utilizing the MBD-seq approach. KL methylation was frequent as it was detected in 55.3 % of breast cancer cases from Saudi Arabia (n = 179) using MethyLight assay. Furthermore, KL is downregulated in breast tumors with its expression induced following treatment with 5-azacytidine. The involvement of KL in breast cancer led us to investigate its relationship in the context of breast cancer, with one of the protagonists of its function, fibroblast growth factor receptor 4 (FGFR4). Overexpression of FGFR4 in breast cancer is frequent in our cohort and this overexpression is associated with poor overall survival. Interestingly, FGFR4 expression is higher in the absence of KL methylation and lower when KL is methylated and presumably silenced, which is suggestive of an intricate relationship between the two factors. In conclusion, our findings further implicate “metabolic” genes or pathways in breast cancer that are disrupted by epigenetic mechanisms and could provide new avenues for understanding this disease in a new context.
Literature
1.
go back to reference Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378:1461–84.CrossRefPubMed Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378:1461–84.CrossRefPubMed
2.
go back to reference Mehmood A, Te OB, Urcia JC, Khan A. Tumor registry annual report. Saudi Arabia: King Faisal Specialist Hospital & Research Center; 2011. Mehmood A, Te OB, Urcia JC, Khan A. Tumor registry annual report. Saudi Arabia: King Faisal Specialist Hospital & Research Center; 2011.
3.
go back to reference Najjar H, Easson A. Age at diagnosis of breast cancer in Arab nations. Int J Surg. 2010;8:448–52.CrossRefPubMed Najjar H, Easson A. Age at diagnosis of breast cancer in Arab nations. Int J Surg. 2010;8:448–52.CrossRefPubMed
5.
go back to reference Merdad A, Gari MA, Hussein S, Al-Khayat S, Tashkandi H, Al-Maghrabi J, et al. Characterization of familial breast cancer in Saudi Arabia. BMC Genomics. 2015;16:S3.CrossRefPubMedPubMedCentral Merdad A, Gari MA, Hussein S, Al-Khayat S, Tashkandi H, Al-Maghrabi J, et al. Characterization of familial breast cancer in Saudi Arabia. BMC Genomics. 2015;16:S3.CrossRefPubMedPubMedCentral
6.
go back to reference Buhmeida A, Dallol A, Merdad A, Al-Maghrabi J, Gari MA, Abu-Elmagd MM, et al. High fibroblast growth factor 19 (fgf19) expression predicts worse prognosis in invasive ductal carcinoma of breast. Tumor Biol. 2014;35:2817–24.CrossRef Buhmeida A, Dallol A, Merdad A, Al-Maghrabi J, Gari MA, Abu-Elmagd MM, et al. High fibroblast growth factor 19 (fgf19) expression predicts worse prognosis in invasive ductal carcinoma of breast. Tumor Biol. 2014;35:2817–24.CrossRef
8.
go back to reference Masuda H, Chikuda H, Suga T, Kawaguchi H, Kuro-o M. Regulation of multiple ageing-like phenotypes by inducible klotho gene expression in klotho mutant mice. Mech Ageing Dev. 2005;126:1274–83.CrossRefPubMed Masuda H, Chikuda H, Suga T, Kawaguchi H, Kuro-o M. Regulation of multiple ageing-like phenotypes by inducible klotho gene expression in klotho mutant mice. Mech Ageing Dev. 2005;126:1274–83.CrossRefPubMed
10.
go back to reference Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281:6120–3.CrossRefPubMedPubMedCentral Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281:6120–3.CrossRefPubMedPubMedCentral
11.
go back to reference Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, et al. Klotho: a tumor suppressor and a modulator of the igf-1 and fgf pathways in human breast cancer. Oncogene. 2008;27:7094–105.CrossRefPubMed Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, et al. Klotho: a tumor suppressor and a modulator of the igf-1 and fgf pathways in human breast cancer. Oncogene. 2008;27:7094–105.CrossRefPubMed
12.
13.
go back to reference Ravikumar P, Ye J, Zhang J, Pinch SN, Hu MC, Kuro-o M, et al. Alpha-klotho protects against oxidative damage in pulmonary epithelia. Am J Physiol Lung Cell Mol Physiol. 2014;307:L566–75.CrossRefPubMedPubMedCentral Ravikumar P, Ye J, Zhang J, Pinch SN, Hu MC, Kuro-o M, et al. Alpha-klotho protects against oxidative damage in pulmonary epithelia. Am J Physiol Lung Cell Mol Physiol. 2014;307:L566–75.CrossRefPubMedPubMedCentral
14.
go back to reference Chen CD, Li H, Liang J, Hixson K, Zeldich E, Abraham CR. The anti-aging and tumor suppressor protein klotho enhances differentiation of a human oligodendrocytic hybrid cell line. J Mol Neurosci. 2015;55:76–90.CrossRefPubMed Chen CD, Li H, Liang J, Hixson K, Zeldich E, Abraham CR. The anti-aging and tumor suppressor protein klotho enhances differentiation of a human oligodendrocytic hybrid cell line. J Mol Neurosci. 2015;55:76–90.CrossRefPubMed
15.
go back to reference Lee J, Jeong DJ, Kim J, Lee S, Park JH, Chang B, et al. The anti-aging gene klotho is a novel target for epigenetic silencing in human cervical carcinoma. Mol Cancer. 2010;9:109.CrossRefPubMedPubMedCentral Lee J, Jeong DJ, Kim J, Lee S, Park JH, Chang B, et al. The anti-aging gene klotho is a novel target for epigenetic silencing in human cervical carcinoma. Mol Cancer. 2010;9:109.CrossRefPubMedPubMedCentral
16.
go back to reference Pan J, Zhong J, Gan LH, Chen SJ, Jin HC, Wang X, et al. Klotho, an anti-senescence related gene, is frequently inactivated through promoter hypermethylation in colorectal cancer. Tumour Biol. 2011;32:729–35.CrossRefPubMed Pan J, Zhong J, Gan LH, Chen SJ, Jin HC, Wang X, et al. Klotho, an anti-senescence related gene, is frequently inactivated through promoter hypermethylation in colorectal cancer. Tumour Biol. 2011;32:729–35.CrossRefPubMed
17.
18.
go back to reference Rubinek T, Shulman M, Israeli S, Bose S, Avraham A, Zundelevich A, et al. Epigenetic silencing of the tumor suppressor klotho in human breast cancer. Breast Cancer Res Treat. 2012;133:649–57.CrossRefPubMed Rubinek T, Shulman M, Israeli S, Bose S, Avraham A, Zundelevich A, et al. Epigenetic silencing of the tumor suppressor klotho in human breast cancer. Breast Cancer Res Treat. 2012;133:649–57.CrossRefPubMed
19.
go back to reference Wang L, Wang X, Wang X, Jie P, Lu H, Zhang S, et al. Klotho is silenced through promoter hypermethylation in gastric cancer. Am J Cancer Res. 2011;1:111–9.PubMed Wang L, Wang X, Wang X, Jie P, Lu H, Zhang S, et al. Klotho is silenced through promoter hypermethylation in gastric cancer. Am J Cancer Res. 2011;1:111–9.PubMed
20.
go back to reference Xie B, Zhou J, Yuan L, Ren F, Liu DC, Li Q, et al. Epigenetic silencing of klotho expression correlates with poor prognosis of human hepatocellular carcinoma. Hum Pathol. 2013;44:795–801.CrossRefPubMed Xie B, Zhou J, Yuan L, Ren F, Liu DC, Li Q, et al. Epigenetic silencing of klotho expression correlates with poor prognosis of human hepatocellular carcinoma. Hum Pathol. 2013;44:795–801.CrossRefPubMed
22.
go back to reference Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical fgf receptor into a specific receptor for fgf23. Nature. 2006;444:770–4.CrossRefPubMed Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical fgf receptor into a specific receptor for fgf23. Nature. 2006;444:770–4.CrossRefPubMed
23.
go back to reference Liu R, Li J, Xie K, Zhang T, Lei Y, Chen Y, et al. Fgfr4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer. Cancer Res. 2013;73:5926–35.CrossRefPubMed Liu R, Li J, Xie K, Zhang T, Lei Y, Chen Y, et al. Fgfr4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer. Cancer Res. 2013;73:5926–35.CrossRefPubMed
24.
go back to reference Luo Y, Yang C, Ye M, Jin C, Abbruzzese JL, Lee MH, et al. Deficiency of metabolic regulator fgfr4 delays breast cancer progression through systemic and microenvironmental metabolic alterations. Cancer Metab. 2013;1:21.CrossRefPubMedPubMedCentral Luo Y, Yang C, Ye M, Jin C, Abbruzzese JL, Lee MH, et al. Deficiency of metabolic regulator fgfr4 delays breast cancer progression through systemic and microenvironmental metabolic alterations. Cancer Metab. 2013;1:21.CrossRefPubMedPubMedCentral
25.
go back to reference Marme F, Werft W, Benner A, Burwinkel B, Sinn P, Sohn C, et al. Fgfr4 arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer. Ann Oncol. 2010;21:1636–42.CrossRefPubMed Marme F, Werft W, Benner A, Burwinkel B, Sinn P, Sohn C, et al. Fgfr4 arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer. Ann Oncol. 2010;21:1636–42.CrossRefPubMed
26.
go back to reference Xu B, Tong N, Chen SQ, Hua LX, Wang ZJ, Zhang ZD, et al. Fgfr4 gly388arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls. BMC Cancer. 2011;11:84.CrossRefPubMedPubMedCentral Xu B, Tong N, Chen SQ, Hua LX, Wang ZJ, Zhang ZD, et al. Fgfr4 gly388arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls. BMC Cancer. 2011;11:84.CrossRefPubMedPubMedCentral
28.
go back to reference Salmon-Divon M, Dvinge H, Tammoja K, Bertone P. PeakAnalyzer: genome-wide annotation of chromatin binding and modification loci. BMC Bioinformatics. 2010;11:415.CrossRefPubMedPubMedCentral Salmon-Divon M, Dvinge H, Tammoja K, Bertone P. PeakAnalyzer: genome-wide annotation of chromatin binding and modification loci. BMC Bioinformatics. 2010;11:415.CrossRefPubMedPubMedCentral
29.
30.
go back to reference Dallol A, Al-Ali W, Al-Shaibani A, Al-Mulla F. Analysis of DNA methylation in ffpe tissues using the MethyLight technology. Methods Mol Biol. 2011;724:191–204. Dallol A, Al-Ali W, Al-Shaibani A, Al-Mulla F. Analysis of DNA methylation in ffpe tissues using the MethyLight technology. Methods Mol Biol. 2011;724:191–204.
31.
go back to reference Abu-Elmagd M, Ishii Y, Cheung M, Rex M, Le Rouedec D, Scotting PJ. Csox3 expression and neurogenesis in the epibranchial placodes. Dev Biol. 2001;237:258–69.CrossRefPubMed Abu-Elmagd M, Ishii Y, Cheung M, Rex M, Le Rouedec D, Scotting PJ. Csox3 expression and neurogenesis in the epibranchial placodes. Dev Biol. 2001;237:258–69.CrossRefPubMed
Metadata
Title
Frequent methylation of the KLOTHO gene and overexpression of the FGFR4 receptor in invasive ductal carcinoma of the breast
Authors
Ashraf Dallol
Abdelbaset Buhmeida
Adnan Merdad
Jaudah Al-Maghrabi
Mamdooh A. Gari
Muhammad M. Abu-Elmagd
Aisha Elaimi
Mourad Assidi
Adeel G. Chaudhary
Adel M. Abuzenadah
Taoufik Nedjadi
Eramah Ermiah
Shadi S. Alkhayyat
Mohammed H. Al-Qahtani
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3733-3

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine